Thursday - November 4, 2021

Bayer announces Christoph Koenen as new Global Head of Clinical Development and Operations within Pharmaceuticals Research and Development at Bayer

Berlin, Germany, November 4, 2021 – Bayer today announced Christoph Koenen as the new Global Head of Clinical Development and Operations within Research and Development at its Pharmaceuticals Division, effective January 1, 2022.

“We are very pleased to welcome Christoph Koenen to our R&D organization. Christoph brings with him broad development experience and a strong track record in cardiovascular and metabolic research in both the academic and industry settings,” said Dr. Christian Rommel, Head of Research and Development and Member of the Pharmaceuticals Executive Committee of Bayer AG. “He has deep knowledge in harnessing external partnerships and outstanding scientific collaborations with professional networks and health authorities worldwide.”

Christoph Koenen joins Bayer from Otsuka Pharmaceutical, where he most recently held the position of Chief Medical Officer. Prior to this, he held multiple senior leadership positions in clinical development at GlaxoSmithKline, Novo Nordisk, and Bristol Myers Squibb.

Christoph Koenen received his MD from Ruprecht-Karls-University, School of Medicine, Heidelberg, Germany, and is board-certified in internal medicine and diabetology. He received his MBA from Schiller International University, Florida/Heidelberg. Christoph Koenen practiced his residency in Internal Medicine with St Josefs Hospital, the teaching hospital of the University of Heidelberg, Germany. Through his professional experience, he has worked and lived in the United States, Germany, and various other European countries.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Find more information at https://pharma.bayer.com/
Follow us on Facebook: http://www.facebook.com/bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Download Center
0
file(s) collected

View Download Center

Contact


Pamela Cohen

R&D and Science
Phone +49 30 468 192038